STEP 1 Trial Summary: What Semaglutide Actually Showed

STEP 1 is the trial that moved semaglutide from an interesting drug to a cultural event. In adults with overweight or obesity, mean weight change at 68 weeks was -14.9% with semaglutide 2.4 mg versus -2.4% with placebo, both alongside lifestyle intervention. [1]

That was genuinely important. But STEP 1 is often misread as proof that obesity medicine has been solved. It has not. The trial proved strong efficacy in a selected population under trial conditions. It did not abolish relapse, side effects, cost, or the need for maintenance planning. [1,2]

The trial design

The study enrolled adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, and compared once-weekly semaglutide 2.4 mg plus lifestyle intervention with placebo plus lifestyle intervention over 68 weeks. [1] This was a foundational efficacy trial. Its job was to answer whether semaglutide produced clinically meaningful weight loss. It did.

What the results showed

A far greater proportion of participants on semaglutide achieved thresholds such as 5%, 10%, and 15% weight reduction. This matters because these are the ranges where blood pressure, glycaemic control, fatty liver, and mechanical symptoms often begin to move in clinical practice. [1] The side-effect profile was led mainly by gastrointestinal adverse events, which is unsurprising for the GLP-1 class. [1,2]

What most articles miss

STEP 1 was not a maintenance trial. It tells you what can be achieved over 68 weeks on treatment. It does not tell you what happens after stopping. That question is better addressed in STEP 4 and off-treatment extension data. [3]

The population also excluded some of the clinical complexity seen in practice. Real-world care includes more comorbidity, more medication burden, and more inconsistent adherence. Lifestyle support existed in both arms, so the results do not mean lifestyle is irrelevant. They mean lifestyle alone did not produce the same result. [1]

What STEP 1 gives clinicians and patients

STEP 1 gives clinicians and patients a legitimate evidence base for serious pharmacological treatment of obesity. It supports semaglutide as more than a modest adjunct. But it also implies a higher standard of follow-up. The bigger the effect, the less sensible it is to treat the medication as a casual consumer purchase.

When to involve your clinician

Early if nausea, vomiting, or reduced intake are compromising hydration, exercise, or other medication tolerance. If you are losing weight but not preserving strength. Or if the drug is being started alongside complex antihypertensive or diabetes therapy. [2]

When to seek urgent help

Severe abdominal pain, persistent vomiting, dehydration, possible gallbladder symptoms, or suspected pancreatitis. [2]

Bottom line

STEP 1 deserved the attention it received. Semaglutide produced weight loss at a level previous drug therapy rarely approached. But the trial's real value lies in giving obesity treatment medical seriousness, not in licensing complacency. [1,2]